Artículos con órdenes de acceso público - Stephane ChampiatMás información
No disponibles en ningún lugar: 3
Intratumoral immunotherapy: from trial design to clinical practice
S Champiat, L Tselikas, S Farhane, T Raoult, M Texier, E Lanoy, ...
Clinical Cancer Research 27 (3), 665-679, 2021
Órdenes: National Institute of Health and Medical Research, France
Intratumoral immunotherapy: is it ready for prime time?
M Ghosn, L Tselikas, S Champiat, F Deschamps, B Bonnet, É Carre, ...
Current Oncology Reports 25 (8), 857-867, 2023
Órdenes: National Institute of Health and Medical Research, France
Exceptional Response to Dual Colony-Stimulating Factor 1 Receptor/PD-L1 Targeting After Primary Resistance to PD-1 Inhibition in a Patient With a Metastatic Uveal Melanoma
S Champiat, H Salaün, F Lucibello, JY Scoazec, B Besse, AI Lalanne, ...
JCO Precision Oncology 7, e2200363, 2023
Órdenes: National Institute of Health and Medical Research, France, Agence Nationale …
Disponibles en algún lugar: 18
Intratumoural administration and tumour tissue targeting of cancer immunotherapies
I Melero, E Castanon, M Alvarez, S Champiat, A Marabelle
Nature Reviews Clinical Oncology 18 (9), 558-576, 2021
Órdenes: European Commission, Gobierno de España
Tarlatamab, a first-in-class DLL3-targeted bispecific T-cell engager, in recurrent small-cell lung cancer: an open-label, phase I study
L Paz-Ares, S Champiat, WV Lai, H Izumi, R Govindan, M Boyer, ...
Journal of Clinical Oncology 41 (16), 2893-2903, 2023
Órdenes: US National Institutes of Health
Inflammatory gastrointestinal diseases associated with PD-1 blockade antibodies
M Collins, JM Michot, FX Danlos, C Mussini, E Soularue, C Mateus, ...
Annals of Oncology 28 (11), 2860-2865, 2017
Órdenes: National Institute of Health and Medical Research, France
Hypermutated tumours in the era of immunotherapy: the paradigm of personalised medicine
L Nebot-Bral, D Brandao, L Verlingue, E Rouleau, O Caron, E Despras, ...
European journal of cancer 84, 290-303, 2017
Órdenes: National Institute of Health and Medical Research, France
Anti-CSF-1R emactuzumab in combination with anti-PD-L1 atezolizumab in advanced solid tumor patients naïve or experienced for immune checkpoint blockade
C Gomez-Roca, P Cassier, D Zamarin, JP Machiels, JLP Gracia, FS Hodi, ...
Journal for immunotherapy of cancer 10 (5), 2022
Órdenes: US National Institutes of Health
PD-1 blockade in solid tumors with defects in polymerase epsilon
B Rousseau, I Bieche, E Pasmant, N Hamzaoui, N Leulliot, L Michon, ...
Cancer discovery 12 (6), 1435-1448, 2022
Órdenes: US National Institutes of Health, Swiss Cancer League
Influence of HAART on alternative reading frame immune responses over the course of HIV-1 infection
S Champiat, RAS Raposo, NJ Maness, JL Lehman, SE Purtell, ...
PLoS One 7 (6), e39311, 2012
Órdenes: US National Institutes of Health
First-in-human phase I study of the OX40 agonist GSK3174998 with or without pembrolizumab in patients with selected advanced solid tumors (ENGAGE-1)
S Postel-Vinay, VK Lam, W Ros, TM Bauer, AR Hansen, DC Cho, FS Hodi, ...
Journal for immunotherapy of cancer 11 (3), 2023
Órdenes: US National Institutes of Health
Transcriptional errors in human immunodeficiency virus type 1 generate targets for T-cell responses
KE Garrison, S Champiat, VA York, AT Agrawal, EG Kallas, JN Martin, ...
Clinical and Vaccine Immunology 16 (9), 1369-1371, 2009
Órdenes: US National Institutes of Health
Predicting Immunotherapy outcomes in older patients with solid tumors using the LIPI score
M Pierro, C Baldini, E Auclin, H Vincent, A Varga, P Martin Romano, ...
Cancers 14 (20), 5078, 2022
Órdenes: Gobierno de España
Genomic instability and protumoral inflammation are associated with primary resistance to anti–PD-1+ antiangiogenesis in malignant pleural mesothelioma
FX Danlos, M Texier, B Job, S Mouraud, L Cassard, C Baldini, A Varga, ...
Cancer Discovery 13 (4), 858-879, 2023
Órdenes: European Commission, Agence Nationale de la Recherche
Human endogenous retrovirus expression is upregulated in the breast cancer microenvironment of HIV infected women: a pilot study
G Curty, GA Beckerle, LP Iñiguez, RL Furler, PS De Carvalho, JL Marston, ...
Frontiers in oncology 10, 553983, 2020
Órdenes: US National Institutes of Health
T cells target APOBEC3 proteins in human immunodeficiency virus type 1-infected humans and simian immunodeficiency virus-infected Indian rhesus macaques
S Champiat, KE Garrison, RAS Raposo, BJ Burwitz, J Reed, R Tandon, ...
Journal of virology 87 (11), 6073-6080, 2013
Órdenes: US National Institutes of Health
Paradoxical cancer cell stimulation by IFNγ drives tumor hyperprogression upon checkpoint blockade immunotherapy
S Champiat, A Marabelle
Cancer Cell 41 (2), 229-231, 2023
Órdenes: National Institute of Health and Medical Research, France
Lever la tolérance immunitaire en cancérologie
M Desbois, S Champiat, N Chaput
Bulletin du Cancer 102 (1), 34-52, 2015
Órdenes: National Institute of Health and Medical Research, France
Epigenetic gene alterations in metastatic solid tumours: Results from the prospective precision medicine MOSCATO and MATCH-R trials
P Martin-Romano, L Colmet-Daage, D Morel, C Baldini, L Verlingue, ...
European Journal of Cancer 173, 133-145, 2022
Órdenes: National Institute of Health and Medical Research, France, Agence Nationale …
Epigenetic genes alterations in metastatic solid tumors: results from the prospective precision medicine MOSCATO and MATCH-R trials
S Postel-Vinay, P Martin-Romano, L Colmet-Daage, D Morel, C Baldini, ...
Órdenes: National Institute of Health and Medical Research, France, Agence Nationale …
La información de publicación y financiación se determina de forma automática mediante un programa informático